2026 / 03

DOI: 10.24075/brsmu.2026.025
Copyright: © 2026 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Appropriateness of prescribing alfacalcidol in secondary hyperparathyroidism in dialysis patients: a retrospective study

Saadoon SJ1 , Atiyah AM2 , Ibrahim AH2 , Mostafa FM2
About authors

1 College of Pharmacy, University of Thi-Qar, Thi-Qar, Iraq

2 College of Pharmacy, Al-Ayen Iraqi University, AUIQ, An Nasiriyah, Iraq

Correspondence should be addressed: Fatma M. Mostafa
Thi-Qar, 64001, Iraq; moc.liamg@999888afatsomamtaf

About paper

Acknowledgements: the authors would like to thank the staff and administration of the hemodialysis units in An-Naseria, Iraq, for their cooperation and support in accessing patient records. The authors also express gratitude to the College of Pharmacy, University of Thi-Qar, and Al-Ayen Iraqi University for providing logistical support.

Author contribution: Fatma M. Mostafa — conceptualization, study design, data collection, data analysis, manuscript drafting, and final approval; Sarah Jaafar Saadoon — data collection, visualization, review, and manuscript revision; Ammar Mohammed Atiyah — data interpretation, statistical analysis (SPSS), and critical revision of the manuscript; Ahmed H. Ibrahim — data validation, manuscript editing, and final approval.

Compliance with ethical standards: this retrospective study was conducted in accordance with the ethical standards, the research was approved by the Research Ethics Committee of Al-Ayen Iraqi University under approval number AUIQ-REC-2025-003. Due to the retrospective nature of this study using anonymized patient records, the requirement for informed consent was waived by the ethics committee.

Received: 2026-04-13 Accepted: 2026-05-16 Published online: 2026-05-30
|
  1. Stack BC. Secondary hyperparathyroidism. Otolaryngologic Clinics of North America. 2024; 57 (1): 99–110.
  2. Xiang Z, et al. Mechanism of calcitriol regulating parathyroid cells in secondary hyperparathyroidism. Frontiers in Pharmacology. 2022; 13: 1020858.
  3. Habas Sr E, et al. Secondary hyperparathyroidism in chronic kidney disease: pathophysiology and management. Cureus. 2021; 13 (7).
  4. Magagnoli L, Ciceri P, Cozzolino M. Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, current treatments and investigational drugs. Expert Opinion on Investigational Drugs. 2024; 33 (8): 775–89.
  5. Ketteler M, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney international. 2017; 92 (1): 26–36.
  6. Kantartzi K, et al. Vitamin D and Vitamin D Analogues in Hemodialysis Patients: A Review of the Literature. International Journal of Molecular Sciences. 2025; 26 (23): 11550.
  7. Hou Y-C, et al. Role of calcimimetics in treating bone and mineral disorders related to chronic kidney disease. Pharmaceuticals. 2022; 15 (8): 952.
  8. Brandenburg V, Ketteler M. Vitamin D and secondary hyperparathyroidism in chronic kidney disease: a critical appraisal of the past, present, and the future. Nutrients. 2022; 14 (15): 3009.
  9. Chao C-T, et al. Adynamic bone disorder in chronic kidney disease: meta-analysis and narrative review of potential biomarkers as diagnosis and therapeutic targets. Renal Failure. 2025; 47 (1): 2530162.
  10. Strugnell SA, et al. Evaluation of therapies for secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. Kidney Diseases. 2023; 9 (3): 206–17.
  11. Weber T, et al. Symptoms of primary hyperparathyroidism in men and women: the same but different? Visceral medicine. 2020; 36 (1): 41–47.
  12. Xu Y, et al. Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease. Clinical kidney journal. 2021; 14 (10): 2213–20.
  13. De Vincentis S, et al. How much vitamin D is too much? A case report and review of the literature. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders). 2021; 21 (9): 1653–9.
  14. El-Arbagy A, et al. Assessment of vitamin D in hemodialysis patients. Menoufia Medical Journal. 2020; 33 (1): 122–123.
  15. Bellavia D, et al. Vitamin D level between calcium-phosphorus homeostasis and immune system: new perspective in osteoporosis. Current osteoporosis reports. 2024; 22 (6): 599–610.
  16. Tobias DK, et al. Association of body weight with response to vitamin D supplementation and metabolism. JAMA network open. 2023; 6 (1): e2250681–e2250681.
  17. Barghi M, et al. Serum levels of vitamin D, calcium, phosphorus, and oxidative parameters in healthy and diabetic people. Functional Foods in Health and Disease-Online I. 2021; 11 (5): 238–45.
  18. Auguste BL, Bargman J. RE: Misconception for the cause of vitamin D toxicity. 2025.
  19. Hussain F, et al. Assessment of Vitamin D Levels and Bone-Related Biochemical Markers in Healthy Adults in Pakistan: Influence of Socio-Demographic and Environmental Factors: Vitamin D Levels and Bone-Related Biochemical Markers in Healthy Adults. Pakistan Journal of Health Sciences. 2025: 194–9.
  20. Wolf M, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney international. 2007; 72 (8): 1004–13.
  21. Graidis S, Papavramidis TS, Papaioannou M. Vitamin D and acute kidney injury: A two-way causality relation and a predictive, prognostic, and therapeutic role of vitamin D. Frontiers in nutrition. 2021; 7: 630951.
  22. Franczyk B, Rysz J, Gluba-Sagr A. Impact of Serum Phosphate, Potassium and Other Electrolyte Levels on Sudden Cardiac Death and Cardiovascular Mortality in Haemodialysis and Peritoneal Dialysis: A Systematic Review and Meta-Analysis. Biomedicines. 2026;14 (3): 605.